{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:44:13Z","timestamp":1773672253507,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41030-025-00330-1","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:59:18Z","timestamp":1763729958000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast"],"prefix":"10.1007","volume":"12","author":[{"given":"Patrick A.","family":"Flume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego J.","family":"Maselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"3","key":"330_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","volume":"10","author":"S Aliberti","year":"2022","unstructured":"Aliberti S, Goeminne PC, O\u2019Donnell AE, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med. 2022;10(3):298\u2013306. https:\/\/doi.org\/10.1016\/S2213-2600(21)00277-0.","journal-title":"Lancet Respir Med"},{"issue":"10150","key":"330_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","volume":"392","author":"PA Flume","year":"2018","unstructured":"Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392(10150):880\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(18)31767-7.","journal-title":"Lancet"},{"issue":"6","key":"330_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMra2202819","volume":"387","author":"AE O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell AE. Bronchiectasis - a clinical review. N Engl J Med. 2022;387(6):533\u201345. https:\/\/doi.org\/10.1056\/NEJMra2202819.","journal-title":"N Engl J Med"},{"issue":"4","key":"330_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1479972317709649","volume":"14","author":"D Weycker","year":"2017","unstructured":"Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis. 2017;14(4):377\u201384. https:\/\/doi.org\/10.1177\/1479972317709649.","journal-title":"Chron Respir Dis"},{"issue":"7","key":"330_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","volume":"11","author":"JD Chalmers","year":"2023","unstructured":"Chalmers JD, Polverino E, Crichton ML, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis Registry (EMBARC). Lancet Respir Med. 2023;11(7):637\u201349. https:\/\/doi.org\/10.1016\/S2213-2600(23)00093-0.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"330_CR6","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1183\/13993003.00961-2015","volume":"46","author":"MA Martinez-Garcia","year":"2015","unstructured":"Martinez-Garcia MA, Sanchez CP, Moreno RM. The double-edged sword of neutrophilic inflammation in bronchiectasis. Eur Respir J. 2015;46(4):898\u2013900. https:\/\/doi.org\/10.1183\/13993003.00961-2015.","journal-title":"Eur Respir J"},{"issue":"2","key":"330_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.chest.2017.03.056","volume":"152","author":"E Polverino","year":"2017","unstructured":"Polverino E, Rosales-Mayor E, Dale GE, Dembowsky K, Torres A. The role of neutrophil elastase inhibitors in lung diseases. Chest. 2017;152(2):249\u201362. https:\/\/doi.org\/10.1016\/j.chest.2017.03.056.","journal-title":"Chest"},{"issue":"4","key":"330_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1055\/s-0041-1730891","volume":"42","author":"HR Keir","year":"2021","unstructured":"Keir HR, Chalmers JD. Pathophysiology of bronchiectasis. Semin Respir Crit Care Med. 2021;42(4):499\u2013512. https:\/\/doi.org\/10.1055\/s-0041-1730891.","journal-title":"Semin Respir Crit Care Med"},{"key":"330_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01126-2025","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Haworth CS, Flume P, et al. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis. Eur Respir J. 2025. https:\/\/doi.org\/10.1183\/13993003.01126-2025.","journal-title":"Eur Respir J"},{"key":"330_CR10","doi-asserted-by":"publisher","unstructured":"Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49(6). https:\/\/doi.org\/10.1183\/13993003.00051-2017.","DOI":"10.1183\/13993003.00051-2017"},{"issue":"11","key":"330_CR11","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","volume":"197","author":"JD Chalmers","year":"2018","unstructured":"Chalmers JD, Aliberti S, Filonenko A, et al. Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis. Am J Respir Crit Care Med. 2018;197(11):1410\u201320. https:\/\/doi.org\/10.1164\/rccm.201711-2202OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"330_CR12","doi-asserted-by":"publisher","unstructured":"Flume PA, Feliciano J, Lucci M, et al. Pulmonary exacerbations in insured patients with bronchiectasis over 2 years. ERJ Open Res. 2023;9(4). https:\/\/doi.org\/10.1183\/23120541.00021-2023.","DOI":"10.1183\/23120541.00021-2023"},{"issue":"1","key":"330_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccm.2021.12.004","volume":"43","author":"AE O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell AE. Airway clearance and mucoactive therapies in bronchiectasis. Clin Chest Med. 2022;43(1):157\u201363. https:\/\/doi.org\/10.1016\/j.ccm.2021.12.004.","journal-title":"Clin Chest Med"},{"key":"330_CR14","doi-asserted-by":"publisher","unstructured":"Herrero-Cortina B, Lee AL, Oliveira A, et al. European Respiratory Society statement on airway clearance techniques in adults with bronchiectasis. Eur Respir J. 2023;62(1). https:\/\/doi.org\/10.1183\/13993003.02053-2022.","DOI":"10.1183\/13993003.02053-2022"},{"issue":"4","key":"330_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1183\/09031936.00003709","volume":"34","author":"MR Loebinger","year":"2009","unstructured":"Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34(4):843\u20139. https:\/\/doi.org\/10.1183\/09031936.00003709.","journal-title":"Eur Respir J"},{"issue":"3","key":"330_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cmi.2020.04.007","volume":"27","author":"MA Martinez-Garcia","year":"2021","unstructured":"Martinez-Garcia MA, Oscullo G, Posadas T, et al. Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis. Clin Microbiol Infect. 2021;27(3):428\u201334. https:\/\/doi.org\/10.1016\/j.cmi.2020.04.007.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"330_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","volume":"7","author":"JD Chalmers","year":"2019","unstructured":"Chalmers JD, Boersma W, Lonergan M, et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med. 2019;7(10):845\u201354. https:\/\/doi.org\/10.1016\/S2213-2600(19)30191-2.","journal-title":"Lancet Respir Med"},{"key":"330_CR18","doi-asserted-by":"publisher","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3). https:\/\/doi.org\/10.1183\/13993003.00629-2017.","DOI":"10.1183\/13993003.00629-2017"},{"issue":"6","key":"330_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/thorax-2024-221825","volume":"80","author":"J Pollock","year":"2025","unstructured":"Pollock J, Polverino E, Dhar R, et al. Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC). Thorax. 2025;80(6):358\u201368. https:\/\/doi.org\/10.1136\/thorax-2024-221825.","journal-title":"Thorax"},{"issue":"14","key":"330_CR20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s40265-022-01785-1","volume":"82","author":"M Mart\u00ednez-Garc\u00eda","year":"2022","unstructured":"Mart\u00ednez-Garc\u00eda M, Oscullo G, Garc\u00eda-Ortega A, Matera MG, Rogliani P, Cazzola M. Inhaled corticosteroids in adults with non-cystic fibrosis bronchiectasis: from bench to bedside. A narrative review. Drugs. 2022;82(14):1453\u201368. https:\/\/doi.org\/10.1007\/s40265-022-01785-1.","journal-title":"Drugs"},{"key":"330_CR21","doi-asserted-by":"publisher","first-page":"107217","DOI":"10.1016\/j.rmed.2023.107217","volume":"211","author":"PA Flume","year":"2023","unstructured":"Flume PA, Basavaraj A, Garcia B, et al. Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis. Respir Med. 2023;211:107217. https:\/\/doi.org\/10.1016\/j.rmed.2023.107217.","journal-title":"Respir Med"},{"issue":"2","key":"330_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/resp.12219","volume":"19","author":"PC Goeminne","year":"2014","unstructured":"Goeminne PC, Vandooren J, Moelants EA, et al. The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. Respirology. 2014;19(2):203\u201310. https:\/\/doi.org\/10.1111\/resp.12219.","journal-title":"Respirology"},{"issue":"10","key":"330_CR23","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","volume":"195","author":"JD Chalmers","year":"2017","unstructured":"Chalmers JD, Moffitt KL, Suarez-Cuartin G, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med. 2017;195(10):1384\u201393. https:\/\/doi.org\/10.1164\/rccm.201605-1027OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"330_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/biomedicines10051044","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang X, Olveira C, Gir\u00f3n R, et al. Blood neutrophil counts define specific clusters of bronchiectasis patients: a hint to differential clinical phenotypes. Biomedicines. 2022;10(5):1044.","journal-title":"Biomedicines"},{"issue":"2","key":"330_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jcf.2013.12.009","volume":"13","author":"MW Konstan","year":"2014","unstructured":"Konstan MW, D\u00f6ring G, Heltshe SL, et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros. 2014;13(2):148\u201355. https:\/\/doi.org\/10.1016\/j.jcf.2013.12.009.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"330_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jcf.2015.07.009","volume":"15","author":"A Gaggar","year":"2016","unstructured":"Gaggar A, Chen J, Chmiel JF, et al. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016;15(2):227\u201333. https:\/\/doi.org\/10.1016\/j.jcf.2015.07.009.","journal-title":"J Cyst Fibros"},{"issue":"15","key":"330_CR27","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1111\/bph.13515","volume":"173","author":"P Gardiner","year":"2016","unstructured":"Gardiner P, Wikell C, Clifton S, Shearer J, Benjamin A, Peters SA. Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity. Br J Pharmacol. 2016;173(15):2390\u2013401. https:\/\/doi.org\/10.1111\/bph.13515.","journal-title":"Br J Pharmacol"},{"issue":"22","key":"330_CR28","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","volume":"383","author":"JD Chalmers","year":"2020","unstructured":"Chalmers JD, Haworth CS, Metersky ML, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2021713.","journal-title":"N Engl J Med"},{"issue":"16","key":"330_CR29","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","volume":"392","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Burgel P-R, Daley CL, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2025;392(16):1569\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2411664.","journal-title":"N Engl J Med"},{"key":"330_CR30","doi-asserted-by":"publisher","unstructured":"Chalmers JD, Shteinberg M, Mall MA, et al. Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study. Eur Respir J. 2025;65(1). https:\/\/doi.org\/10.1183\/13993003.01551-2024.","DOI":"10.1183\/13993003.01551-2024"},{"issue":"5","key":"330_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/s2213-2600(25)00019-0","volume":"13","author":"NS Zhong","year":"2025","unstructured":"Zhong NS, Qiu R, Cao J, et al. Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2025;13(5):414\u201324. https:\/\/doi.org\/10.1016\/s2213-2600(25)00019-0.","journal-title":"Lancet Respir Med"},{"key":"330_CR32","unstructured":"BRINSUPRI (brensocatib) Full Prescribing Information. Insmed Incorporated; 2025; accessed September 2025 [Available from: https:\/\/www.brinsupri.com\/pdfs\/full-prescribing-information.pdf.]"},{"issue":"3","key":"330_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.chest.2023.05.016","volume":"164","author":"J Pollock","year":"2023","unstructured":"Pollock J, Goeminne PC. Eosinophils in bronchiectasis: a U-turn for bronchiectasis management. Chest. 2023;164(3):561\u20133. https:\/\/doi.org\/10.1016\/j.chest.2023.05.016.","journal-title":"Chest"},{"key":"330_CR34","doi-asserted-by":"publisher","first-page":"A5239","DOI":"10.1164\/ajrccm.2025.211","volume":"211","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Flume PA, De Soyza A, et al. Efficacy of brensocatib in patients with eosinophilic bronchiectasis: an analysis of the ASPEN trial. Am J Respir Crit Care Med. 2025;211:A5239. https:\/\/doi.org\/10.1164\/ajrccm.2025.211.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00330-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:31:06Z","timestamp":1773667866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00330-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["330"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00330-1","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patrick A. Flume reports consulting fees and research support from Insmed Incorporated. Diego J. Maselli reports consulting fees from Insmed Incorporated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals conducted by the authors. The podcast transcript has been edited for clarity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}